JUNS vs MRNA · rev $21.8K vs rev $145.0M
Jupiter Neurosciences, Inc. Common Stock (JUNS) versus Moderna Inc (MRNA) — a side-by-side from cached financials, not a winner call.
Jupiter Neurosciences, Inc. Common Stock (JUNS) is a biotechnology company listed on NASDAQ.
Moderna Inc (MRNA) is a biotechnology company listed on NASDAQ. It is led by Stéphane Bancel M.B.A..
Latest reported JUNS revenue for 2025-12-31 was $21.8K. Net income was -$8.6M. JUNS currently screens at market cap $10.0M.
Latest reported MRNA revenue for 2026-06-30 was $145.0M. Net income was -$782.0M. Revenue was down 62.7% from 2026-03-31 to 2026-06-30. MRNA currently screens at market cap $24.52B.
JUNS currently screens at market cap $10.0M. MRNA currently screens at market cap $24.52B.
Not investment advice. Open the JUNS and MRNA stock pages for the full models.
Not investment advice.